PharmaLogic opens PET radiopharmaceutical facility in Atlanta

PharmaLogic Holdings has opened a PET radiopharmaceutical manufacturing facility in Atlanta, expanding its U.S. production network for diagnostic and therapeutic radiopharmaceuticals.

The company said the facility will increase production capacity and support research and development of novel radiopharmaceuticals. Its Atlanta location is intended to improve delivery of time-sensitive PET agents to hospitals and imaging centers across the Southeast.

PharmaLogic is a contract development and manufacturing organization focused on radiopharmaceuticals. The company described the Atlanta site as part of a broader effort to strengthen domestic radiopharmaceutical manufacturing infrastructure and improve patient access to advanced nuclear medicine agents.

The opening is part of a $250M investment in U.S. radiopharmaceutical infrastructure. PharmaLogic said the Atlanta facility follows recent openings in Cincinnati; the Bronx, NY; Salt Lake City; and Los Angeles.

“The opening of our Atlanta facility marks another critical step in our $250 million investment to address the deficit of radiopharmaceutical infrastructure in the U.S.,” said Etienne Montagut, president and CEO of PharmaLogic.

The company said the site will support access to advanced radiopharmaceuticals in the Southeast and surrounding areas. It also described the facility as a hub for development of next-generation radiopharmaceuticals.

PET radiopharmaceutical manufacturing is highly location-sensitive because many agents have short physical half-lives and require fast delivery after production. Regional manufacturing sites can therefore affect whether hospitals and imaging centers can reliably schedule PET studies and support emerging clinical programs.

The new Atlanta site is also relevant to theranostics and drug-development workflows. As more diagnostic and therapeutic radiopharmaceuticals move through clinical development and commercialization, production capacity, quality systems, and regional distribution networks are becoming more important to nuclear medicine operations.

PharmaLogic’s network currently delivers more than 2.5M doses annually, according to the company. The firm said the Atlanta expansion adds capacity for both commercial production and research activities.

The Atlanta opening does not announce a specific new tracer approval or clinical trial. The main development is infrastructure: additional PET manufacturing capacity in a region where fast distribution can determine practical access to radiopharmaceutical imaging.